CAR T-Cell Therapy: Optimal Management of AEs

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the main CAR T-cell therapy–associated toxicities in hematologic malignancies.

Bijal Shah, MD, MS, and Michael Wang, MD, discuss management strategies for CAR T-cell therapy–related cytokine release syndrome and neurotoxicity in leukemia and lymphoma.

Bijal Shah, MD, MS, and Michael Wang, MD, discuss navigating the referral process for CAR T-cell therapy in hematologic malignancies.

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the challenges of managing high-risk mantle cell lymphoma.

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, address the issue of financial toxicity in CAR T-cell therapy.

Brian T. Hill, MD, PhD, and Craig Sauter, MD, discuss the promise of allogeneic CAR T-cell products.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss potential directions for CAR T-cell therapy in lymphomas.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, discuss recent data showing that the CAR T-cell production can be shortened.

Craig Sauter, MD, and Brian T. Hill, MD, PhD, consider CAR T-cell therapy in the second-line setting for patients with diffuse large B-cell lymphoma.